XIANGYU MEDICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.91 CNY | -2.92% |
|
-2.48% | -26.98% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -26.98% | 846M | - | ||
| +11.73% | 226B | B | ||
| +9.53% | 188B | B- | ||
| +14.63% | 137B | B- | ||
| +27.47% | 108B | A- | ||
| -0.04% | 63.19B | A- | ||
| +13.73% | 52.26B | B+ | ||
| +4.86% | 51B | B+ | ||
| +7.72% | 43.89B | A | ||
| +7.86% | 38.07B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
- Stock Market
- Equities
- 688626 Stock
- Ratings Xiangyu Medical Co.,Ltd